# Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

Source: https://onco.cc/trials/nct06484153/  
OnCo record `nct06484153` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of fruquintinib and pembrolizumab in colorectal cancer, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, now recruiting.

## Summary

Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma is a phase 2, interventional study registered as NCT06484153 by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, with a registry enrolment figure of 25 participants, started 2024-07-22 and due to reach its primary completion in 2026-07-22. Interventions recorded: Pirfenidone; Fruquintinib; Pembrolizumab. Conditions listed: To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma; To Evaluate Whether Pirfenidone Can Reshape the Tumor Microenvironment in Colorectal Cancer; Combination of Fruquintinib and Anti-PD-1 Antibody Was Reported to Improve Patient Prognosis in Colorectal Cancer. Primary outcome: Progression Free Survival (PFS); Occurrence of Grade 4 toxicity; Occurrence of Grade 3 toxicity. Colorectal eligibility wording from the registry: "Histologically confirmed diagnosis of unresectable locally advanced, recurrent or metastatic colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06484153
- Phase: 2
- Setting: A Randomized Phase 2 Clinical Trial Evaluating Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Patients With Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
- Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Enrolled: 25

## Sources

- ClinicalTrials.gov NCT06484153: https://clinicaltrials.gov/study/NCT06484153

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Fruquintinib](https://onco.cc/drugs/fruquintinib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06484153.json